GSK Gets Boost As Shingles Vaccine Enters Late Stage. AGEN Goes Along For Ride. (GSK, AGEN)

August 26, 2010 · Filed Under shingles · Comment 

GlaxoSmithKline’s (NYSE: GSK) new shingles recently entered phase III trials, and is expected to breeze through these as well. Meanwhile, Antigenics Inc. (NYSE: AGEN) the company responsible for the vaccine’s adjuvant, also experienced a major jump yesterday. Shares of GSK are up .56% today to $37.63. Shares of AGEN are down 3.68% to $0.82, but this should be seen as more of a minor correction after gaining nearly 12% yesterday.

AGEN has traded 508 thousand shares today so far, with an average volume of 557 thousand.

-Michael B. Sauter

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed